SM 04646

Drug Profile

SM 04646

Alternative Names: SM-04646

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Samumed
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 24 Jul 2017 SM 04646 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 19 Jul 2017 Samumed completes a phase I trial in Idiopathic pulmonary fibrosis (In healthy volunteers) in Australia (Intranasal, Inhalant)
  • 18 Jul 2017 Samumed initiates enrolment in a phase I trial in Idiopathic pulmonary fibrosis in Australia (Intranasal, Inhalant) (ACTRN12617000854336)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top